Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. (Q39962064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

main subject

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author

Lisandro D Colantonio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Jorge A Gómez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Nadia Demarteau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Baudouin Standaert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Andrés Pichón-Rivière

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Federico Augustovski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

17 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

5519-5529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chapter 1: HPV in the etiology of human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chapter 8: Screening for cervical cancer in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cervical cancer in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chapter 15: HPV vaccine use in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

The health and economic burden of genital warts in a set of private health plans in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cervical cancer: the Chilean perspective. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Estimating the world cancer burden: Globocan 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Estimating the cost of cervical cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Chile: social protection in health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Need for differential discounting of costs and health effects in cost effectiveness analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Discounting in economic evaluations: stepping forward towards optimal decision rules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Mathematical models of cervical cancer prevention in Latin America and the Caribbean

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Meta-analysis of Pap test accuracy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Cervical cancer screening program of Paraná: cost-effective model in a developing country

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Epidemiology of HPV infection among Mexican women with normal cervical cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Prognostic factors related to cervical cancer survival in Mexican women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Human papillomavirus and invasive cervical cancer in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiânia, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

HPV prevalence among Mexican women with neoplastic and normal cervixes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Design and results of the USA-Mexico border human papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.097

10.1016/J.VACCINE.2009.06.097

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19616499%20AND%20SRC:MED&resulttype=core&format=json

release_tw3aux6wtfhwze3y7tu7onkbgm

2 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tw3aux6wtfhwze3y7tu7onkbgm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference